- In May 2024, Maxwellia, a champion of women’s health, announced the availability of Evana Heavy Period Relief 500mg tablets (containing tranexamic acid) and Ultravana Period Pain Relief 250mg gastro-resistant tablets (containing naproxen) to assist women in managing heavy and painful periods. Evana is an anti-fibrinolytic indicated for reducing heavy menstrual bleeding (HMB), with the potential to decrease flow by up to 60%. It is the only pharmacy brand available specifically for the relief of heavy menstrual bleeding
- In January 2024, Avenacy, a specialty pharmaceutical company focused on providing essential injectable medications, announced the launch of Tranexamic Acid Injection, USP in the United States as a therapeutic generic equivalent to Cyklokapron, as approved by the U.S. Food and Drug Administration. This injection is indicated for short-term use (2 to 8 days) in patients with hemophilia to reduce or prevent bleeding and minimize the need for replacement therapy during and after tooth extraction
- In September 2022, Shilpa Medicare Limited announced the successful innovation of the world’s first topical hemostatic spray containing Tranexamic Acid, which has received approval from the Central Drugs Standard Control Organization (CDSCO). This groundbreaking spray formulation is user-friendly, portable, easy to apply, and serves as a lifesaving tool. It has been clinically validated in humans and through a robust swine trauma model
